menu
    • menu
    [{"orgOrder":0,"company":"Aulos","sponsor":"ATPGroup","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"IL-2 receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aulos \/ ATPGroup","highestDevelopmentStatusID":"4","companyTruncated":"Aulos \/ ATPGroup"},{"orgOrder":0,"company":"Aulos","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Merck Group","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Merck Group"},{"orgOrder":0,"company":"Aulos","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Series A Financing","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Apple Tree Partners","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Apple Tree Partners"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Biolojic Design"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"AU-007","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Inapplicable"},{"orgOrder":0,"company":"Aulos","sponsor":"Biolojic Design","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Aldesleukin","moa":"||IL-2-CD25","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Aulos","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Aulos \/ Biolojic Design","highestDevelopmentStatusID":"7","companyTruncated":"Aulos \/ Biolojic Design"}]

    Find Clinical Drug Pipeline Developments & Deals by Aulos

    Menu

    Aulos

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aulos Bio Doses First Patient in Phase 2 Trial of Avelumab and AU-007 in Lung Cancer

    Details : AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors. It is being evaluated for the treatment of non-small cell lung cancer.

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Inapplicable

    November 27, 2024

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Merck Group

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    Aulos Bioscience Partners with Merck KGaA to Study Bavencio® with AU-007

    Details : Merck KGaA will provide Aulos a free supply of Bavencio to evaluate in combination with AU-007, which is being under clinical investigation for the treatment of solid tumor cancers.

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Undisclosed

    May 15, 2024

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Merck Group

    Deal Size : Undisclosed

    Deal Type : Collaboration

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aulos Doses First Patient in Phase 2 Trial for IL-2 Antibody for Solid Tumors

    Details : AU-007 is an IgG1 monoclonal antibody leveraging IL-2 to eradicate solid tumors, currently in phase 1/2 trials for advanced melanoma and renal cell carcinoma.

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Inapplicable

    January 25, 2024

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-...

    Details : AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. It is under phase 1/2 clinical development for the treatment of solid tumors.

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Inapplicable

    December 18, 2023

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Apple Tree Partners

    Deal Size : $60.0 million

    Deal Type : Series A Financing

    DEALS_DEV arrow-down

    Aulos Bioscience Raises $20 Million in Series A Extension Financing from Apple Tree Partners

    Details : The funds will be used to advance Aulos’ lead human monoclonal antibody candidate, AU-007 that is highly selective to the CD25-binding portion of IL-2, through its initial Phase 2 clinical study in solid tumor cancers.

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Undisclosed

    January 08, 2023

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Apple Tree Partners

    Deal Size : $60.0 million

    Deal Type : Series A Financing

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic ...

    Details : AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor ...

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Inapplicable

    January 02, 2023

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeut...

    Details : AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2.AU-007 leverages IL-2 to reinforce anti-tumor immune effects.

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Inapplicable

    November 10, 2022

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 ...

    Details : AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor ...

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Inapplicable

    May 26, 2022

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Biolojic Design

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumo...

    Details : AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a highly differentiated approach to harnessing the power of interleukin-2 (IL-2) to eradicate solid tumors.

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Inapplicable

    May 05, 2022

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Biolojic Design

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    10

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed

    Aulos

    U.S.A arrow
    BePharma
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Study Phase : Phase I/ Phase II

    Sponsor : Biolojic Design

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Can...

    Details : The trial will evaluate AU-007, a highly differentiated monoclonal antibody that was computationally designed by Biolojic and harnesses the power of the body's own interleukin-2 (IL-2) to eradicate solid cancer tumors.

    Product Name : AU-007

    Product Type : Antibody

    Upfront Cash : Inapplicable

    May 04, 2022

    Lead Product(s) : AU-007,Aldesleukin

    Therapeutic Area : Oncology

    Highest Development Status : Phase I/ Phase II

    Sponsor : Biolojic Design

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth